{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:19:47Z","timestamp":1791443987657,"version":"4.3.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K11515"],"award-info":[{"award-number":["24K11515"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"the Takeda Science Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-38587-4","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:15:03Z","timestamp":1770459303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of venetoclax trough levels on safety and efficacy in the treatment of acute myeloid leukemia"],"prefix":"10.1038","volume":"16","author":[{"given":"Hiromi","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Yamagiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Miyahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsumasa","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Imada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Toubai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Yoshifuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-ichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Miyao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Onda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisaki","family":"Mizumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouhei","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yonezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsaku","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"11","key":"38587_CR1","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jcph.741","volume":"56","author":"AH Salem","year":"2016","unstructured":"Salem, A. H. et al. Effect of Low- and High-Fat meals on the pharmacokinetics of Venetoclax, a selective First-in-Class BCL-2 inhibitor. J. Clin. Pharmacol. 56 (11), 1355\u20131361 (2016).","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"38587_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl. J. Med. 374 (4), 311\u2013322 (2016).","journal-title":"N Engl. J. Med."},{"key":"38587_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev.immunol.16.1.395","volume":"16","author":"DT Chao","year":"1998","unstructured":"Chao, D. T. & Korsmeyer, S. J. BCL-2 family: regulators of cell death. Annu. Rev. Immunol. 16, 395\u2013419 (1998).","journal-title":"Annu. Rev. Immunol."},{"issue":"17","key":"38587_CR4","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","volume":"22","author":"X Niu","year":"2016","unstructured":"Niu, X. et al. Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with Daunorubicin or cytarabine in AML cells. Clin. Cancer Res. 22 (17), 4440\u20134451 (2016).","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"38587_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl. J. Med. 383 (7), 617\u2013629 (2020).","journal-title":"N Engl. J. Med."},{"issue":"22","key":"38587_CR6","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain, N. et al. Ibrutinib and venetoclax for First-Line treatment of CLL. N Engl. J. Med. 380 (22), 2095\u20132103 (2019).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"38587_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo, C. D. et al. Venetoclax combined with decitabine or Azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133 (1), 7\u201317 (2019).","journal-title":"Blood"},{"issue":"2","key":"38587_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo, C. D. et al. Safety and preliminary efficacy of venetoclax with decitabine or Azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 19 (2), 216\u2013228 (2018).","journal-title":"Lancet Oncol."},{"issue":"24","key":"38587_CR9","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei, A. H. et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135 (24), 2137\u20132145 (2020).","journal-title":"Blood"},{"issue":"4","key":"38587_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129 (4), 424\u2013447 (2017).","journal-title":"Blood"},{"issue":"12","key":"38587_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140 (12), 1345\u20131377 (2022).","journal-title":"Blood"},{"issue":"25","key":"38587_CR12","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo, C. D. et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J. Clin. Oncol. 39 (25), 2768\u20132778 (2021).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"38587_CR13","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1016\/S2352-3026(22)00076-X","volume":"9","author":"CA Lachowiez","year":"2022","unstructured":"Lachowiez, C. A. et al. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 9 (5), e350\u2013e360 (2022).","journal-title":"Lancet Haematol."},{"issue":"24","key":"38587_CR14","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","volume":"5","author":"EM Cherry","year":"2021","unstructured":"Cherry, E. M. et al. Venetoclax and Azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 5 (24), 5565\u20135573 (2021).","journal-title":"Blood Adv."},{"issue":"13","key":"38587_CR15","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short, N. J. et al. Azacitidine, Venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-Mutated AML. J. Clin. Oncol. 42 (13), 1499\u20131508 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"38587_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","volume":"39","author":"SK Agarwal","year":"2017","unstructured":"Agarwal, S. K. et al. Management of Venetoclax-Posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin. Ther. 39 (2), 359\u2013367 (2017).","journal-title":"Clin. Ther."},{"issue":"4","key":"38587_CR17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bcp.13175","volume":"83","author":"SK Agarwal","year":"2017","unstructured":"Agarwal, S. K. et al. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br. J. Clin. Pharmacol. 83 (4), 846\u2013854 (2017).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"38587_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hon.2964","volume":"40","author":"D Brackman","year":"2022","unstructured":"Brackman, D. et al. Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-na\u00efve acute myeloid leukemia who are ineligible for intensive chemotherapy. Hematol. Oncol. 40 (2), 269\u2013279 (2022).","journal-title":"Hematol. Oncol."},{"issue":"5","key":"38587_CR19","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/S2352-3026(22)00073-4","volume":"9","author":"J Stemler","year":"2022","unstructured":"Stemler, J. et al. Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European hematology association. Lancet Haematol. 9 (5), e361\u2013e373 (2022).","journal-title":"Lancet Haematol."},{"issue":"5","key":"38587_CR20","doi-asserted-by":"publisher","first-page":"e13807","DOI":"10.1111\/cts.13807","volume":"17","author":"AH Salem","year":"2024","unstructured":"Salem, A. H. & Menon, R. M. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor. Clin. Transl Sci. 17 (5), e13807 (2024).","journal-title":"Clin. Transl Sci."},{"issue":"3","key":"38587_CR21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1124\/dmd.120.000261","volume":"49","author":"M Kumondai","year":"2021","unstructured":"Kumondai, M. et al. Functional characterization of 40 CYP3A4 variants by assessing Midazolam 1\u2032-Hydroxylation and testosterone 6\u2009<\u2009em\u2009> \u03b2-Hydroxylation. Drug Metab. Dispos. 49 (3), 212\u2013220 (2021).","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"38587_CR22","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3390\/pharmaceutics15061680","volume":"15","author":"S De Gregori","year":"2023","unstructured":"De Gregori, S. et al. Pharmacokinetics of venetoclax co-administered with posaconazole in patients with acute myeloid leukemia. Pharmaceutics 15(6), 1680 (2023).","journal-title":"Pharmaceutics"},{"key":"38587_CR23","doi-asserted-by":"publisher","first-page":"122176","DOI":"10.1016\/j.jchromb.2020.122176","volume":"1152","author":"ED Eisenmann","year":"2020","unstructured":"Eisenmann, E. D., Jin, Y., Weber, R. H., Sparreboom, A. & Baker, S. D. Development and validation of a sensitive UHPLC-MS\/MS analytical method for venetoclax in mouse plasma, and its application to Pharmacokinetic studies. J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 1152, 122176 (2020).","journal-title":"J. Chromatogr. B Analyt Technol. Biomed. Life Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38587-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38587-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38587-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:45:16Z","timestamp":1772099116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38587-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38587"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38587-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6994976\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Financial disclosure: This work was supported in part by JSPS KAKENHI Grant Number 24K11515 (JK) and the Takeda Science Foundation (JK).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"7667"}}